ACR 2025 experts explore gout’s deep ties to MetS, insulin resistance & cardiovascular mortality, weighing new data on colchicine, febuxostat & SGLT2 inhibitors.
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.
The FDA has accepted a biologics license application for nano-encapsulated sirolimus with pegylated-adricase (NASP), a combination treatment designed to reduce serum uric acid levels in patients with uncontrolled gout.
The FDA as approved the biosimilar treatments denosumab-nxxp (Bildyos) and denosumab-nxxp (Bilprevda) for all indications of denosumab, their reference product, including osteoporosis in postmenopausal women.
The ACR honors excellence in rheumatology. Meet the 2025 Awards of Distinction recipients, ACR Masters & Distinguished Fellows recognized at ACR Convergence 2025.
Starting Nov. 13, the long-running ACR@Work newsletter is transforming into The Rheum Advocate, delivering the latest updates on advocacy, policy developments, clinical practice support and the issues that matter most to rheumatology professionals.
The ACR’s resolutions at the Interim HOD meeting, held Nov. 14–18, will address non-compete agreements as well as the use of artificial intelligence (AI) in prior authorization processes.